Skip to content
    BCPC
    Earnings call· Mar 2026(Q1 FY26)

    BALCHEM Q1 FY26 earnings call BCPC

    Apr 30, 2026 Source

    Executive summary

    Balchem Q1 FY26 — Record Sales and Adjusted EBITDA Across All Segments

    Balchem delivered a strong start to the year with record Q1 FY26 financial results, driven by healthy demand across all segments and successful market penetration of its specialty nutrients. The company continues to leverage its formulation expertise and branded ingredients, particularly VitaCholine, while navigating geopolitical and macroeconomic dynamics, including rising input costs, through strategic pricing and supply chain management. Management remains confident in sustained top and bottom-line growth for the remainder of 2026.

    Highlights

    5

    • Record first quarter consolidated sales of $271 million, up 8.1% year-over-year.

    • Record quarterly adjusted EBITDA of $74 million, an increase of 12.1%.

    • 27th consecutive quarter of quarterly year-over-year growth in adjusted EBITDA.

    • Gross margin expanded to 37.3% of sales, up 210 basis points year-over-year.

    • Reduced Scope 1 and 2 greenhouse gas emissions by approximately 31% compared to 2020 baseline, surpassing 2030 goal of 25%.

    Concerns

    2

    • Anticipate modest margin compression in Animal Nutrition & Health due to timing lag between petrochemical-based input cost inflation and pricing adjustments.

    • Effective tax rate increased to 23.3% in Q1 FY26 from 22.7% in Q1 FY25 due to state taxes and discrete items.

    Guidance & targets

    5
    CategoryTargetConfidence
    Consolidated quarterly year-over-year growth
    continued growth
    high materiality
    High
    Animal Nutrition & Health segment growth
    continue to drive growth
    medium materiality
    High
    Consolidated top and bottom line growth
    continued growth
    high materiality
    High
    Effective tax rate
    higher in Q2, then lower in H2
    low materiality
    Medium
    Effective tax rate (full year)
    23%
    low materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Human Nutrition & Health
    Driven by growth in both Nutrients and Food Ingredients and Solutions businesses. Favorable mix partially offset by higher manufacturing input costs and operating expenses. Differentiated ingredients and solutions align with consumer shift toward better-for-you nutrition.
    Nutrients business growth: very strong, double-digitsFood Ingredients and Solutions businesses growth: lower to mid-single digits
    		$172 million8.3%—$40 million (GAAP earnings from operations), $43 million (adjusted earnings from operations)
    Animal Nutrition & Health
    Increase driven by higher sales in both monogastric and ruminant businesses. Improved performance with continued adoption of encapsulated rumen-protected nutrients. U.S. monogastric steady, European monogastric improving post-EU antidumping duties. Facing increases in raw material and freight costs.
    Monogastric business growth: higher salesRuminant business growth: higher salesEuropean monogastric business volume improvement: double-digit in Q1
    		$62 million8.6%—$6 million (GAAP earnings from operations), $6 million (adjusted earnings from operations)
    Specialty Products
    Driven by healthy growth in Performance Gases. Record quarterly earnings from operations and adjusted earnings from operations. Performance Gases seeing healthy demand in both U.S. and Europe. Plant Nutrition growth primarily from geographic expansion, with significant margin improvement in Q1.
    		$35 million4.4%—$12 million (GAAP earnings from operations), $13 million (adjusted earnings from operations)

    Operational metrics

    22
    Adjusted EBITDA
    $74 millionup 12.1%
    Q1 FY26

    Record quarterly adjusted EBITDA.

    Adjusted EBITDA growth streak
    27consecutive year-over-year growth
    Q1 FY26

    27th consecutive quarter of quarterly year-over-year growth in adjusted EBITDA.

    Adjusted Net Earnings
    $43 millionup 7.4%
    Q1 FY26

    Record quarterly adjusted net earnings.

    Adjusted EPS
    $1.33up 9%
    Q1 FY26

    Record quarterly adjusted EPS.

    Gross Margin Percent
    37.3%up 210 basis points
    Q1 FY26

    Expanded gross margin percent, driven by sales growth and manufacturing efficiencies, partially offset by raw material inflation.

    Gross Margin Dollars Growth
    14.6%up 14.6%
    Q1 FY26

    Gross margin dollars were $101 million, up 14.6%.

    Non-GAAP Earnings from Operations
    $61 millionup 9.5%
    Q1 FY26

    Record non-GAAP earnings from operations.

    Net Interest Expense
    $2 milliondecrease of $1 million
    Q1 FY26

    Primarily driven by lower outstanding borrowings and lower interest rates.

    Net Debt
    $96 million
    Q1 FY26

    Net debt level at quarter end.

    Leverage Ratio (Net Debt Basis)
    0.3x
    Q1 FY26

    Overall leverage ratio on a net debt basis.

    Effective Tax Rate
    23.3%vs 22.7% in Q1 FY25
    Q1 FY26

    Increase primarily due to an increase in certain state taxes.

    Cash Flows from Operations
    $40 million
    Q1 FY26

    Cash generated from operating activities.

    Cash Balance
    $73 million
    Q1 FY26

    Cash on the balance sheet at quarter end.

    GAAP Diluted EPS Growth
    10.6%increase
    Q1 FY26

    GAAP diluted net earnings per share increased.

    Foreign Currency Exchange Impact on Sales
    2%favorable impact
    Q1 FY26

    Favorable impact to sales growth.

    Scope 1 and 2 Greenhouse Gas Emissions Reduction
    31%vs 2020 baseline
    2025

    Surpassed 2030 goal of 25% reduction.

    Water Withdrawal Reduction
    16%vs 2020 baseline
    2025

    Substantial progress toward 2030 water usage reduction objective.

    Human Nutrition & Health Power Brands Sales %
    40-50%
    current

    Percentage of H&H business from recognized consumer brands, growing faster than other parts of the business.

    Human Nutrition & Health B2B Brands Sales %
    50-60%
    current

    Percentage of H&H business from B2B brands, representing the portion not covered by consumer-recognized power brands.

    Human Nutrition & Health Nutrients Business Growth
    double-digits
    Q1 FY26

    Minerals business performing outstandingly, all nutrients growing nicely.

    Human Nutrition & Health Food Ingredients and Solutions Business Growth
    lower to mid-single digits
    Q1 FY26

    Growth fueled by better-for-you trends in products like meat sticks, high-protein bars, high-fiber beverages, organic cereals.

    Animal Nutrition & Health European Monogastric Volume Improvement
    double-digitimprovement
    Q1 FY26

    Volume improvement following EU antidumping duties, combined with improved pricing.

    Industry KPIs

    1
    MetricValueDetails
    Volume vs price splitdouble-digit volume improvement%

    Product announcements

    1
    ProductTypeDetails
    VitaCholineupdate

    Risks & headwinds

    4
    Petrochemical-based input cost inflationcoming quarters

    significant

    Mitigation: Leverage robust global supply chain, procurement expertise, strong market positions to raise prices where necessary. Expect modest margin compression due to timing lag.

    Supply chain disruptionsongoing

    potential

    Mitigation: Monitor developments closely and adjust accordingly.

    Geopolitical and macroeconomic environmentongoing

    dynamic and evolving

    Mitigation: Well positioned to effectively manage through.

    Increased effective tax rateQ1 FY26, expected higher in Q2

    23.3% in Q1 FY26 vs 22.7% in Q1 FY25

    Mitigation: Anticipated to modulate lower in H2 FY26 towards a 23% full-year planning rate.

    What to watch in Q2 FY26

    4

    Consolidated Adjusted EBITDA Growth

    next quarter
    Current27th consecutive quarter of year-over-year growth
    TargetContinued year-over-year growth

    Why it matters

    Sustained adjusted EBITDA growth is a key indicator of the company's ability to manage costs and pricing in an inflationary environment.

    we do expect to deliver continued quarterly year-over-year growth on a consolidated basis over the coming quarters.

    Q&A highlights

    6

    What percentage of Human Nutrition & Health sales are branded, and what is the long-term potential?

    Branded ingredients, specifically consumer-recognized 'power brands' like VitaCholine, K2VITAL, OptiMSM, and Albion Minerals, make up about 40% to 50% of the Human Nutrition & Health business today. This portion is growing faster than other parts of the business and is expected to become a larger part of the portfolio over time.

    “Our branded ingredients, and let's just talk about Human Nutrition & Health, make up about, I would say, 40% to 50% of our Human Nutrition & Health business today.”

    asked by Bob Labick · answered by Theodore Harris

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Initiatives & VitaCholine Research

    Balchem highlighted significant progress on strategic initiatives, including a newly published peer-reviewed research study on VitaCholine. The study, published in Nutrients, showed VitaCholine intake significantly enhanced functional connectivity within the working memory network in post-menopausal women, suggesting potential benefits for cognitive health in older adults. This expands on previous research supporting fetal brain development, and the company plans further investment in research and marketing to drive market penetration.

    02

    Sustainability Achievements

    The company released its 2025 Sustainability Report, demonstrating commitment to its 2030 goals. Balchem successfully reduced Scope 1 and 2 greenhouse gas emissions by approximately 31% compared to its 2020 baseline, surpassing its 25% reduction goal. Water withdrawal was reduced by approximately 16%, showing substantial progress towards its 25% water usage reduction objective, reflecting strong stewardship of employees, customers, shareholders, and communities.

    03

    Market Environment & Inflation Management

    Balchem continues to see healthy demand across most end markets, particularly Human Nutrition & Health, benefiting from better-for-you trends. The company is entering a period of significant petrochemical-based inflation, primarily impacting the Animal Nutrition & Health segment, and potential supply chain disruption🌐s from geopolitical events. Management plans to leverage its robust global supply chain, procurement expertise, and strong market positions to raise prices where necessary, expecting modest margin compression due to timing lags between cost increases and pricing adjustments.

    04

    International Growth Focus

    Geographic expansion remains a primary strategic focus for Balchem, with the company actively hiring personnel in various international regions around the world. This investment in sales and marketing is contributing to higher growth rates in most international locations compared to the U.S., driven by a lower base. The company is building out the necessary infrastructure to support this strategic initiative and is seeing positive results from these efforts.

    05

    Animal Nutrition & Health Recovery

    The Animal Nutrition & Health segment showed improved performance, with double-digit volume improvement and improved pricing in the European monogastric business following EU antidumping duties. The U.S. monogastric business remained steady, and the ruminant business continued to see adoption of encapsulated rumen-protected nutrients. Management is closely monitoring geopolitical impact🌐s on input costs and freight for this segment, but remains confident in its ability to drive continued growth over time⏳.

    AI-generated summary of the company’s earnings call. Not investment advice.